In addition to the level of tumor infiltrating CD4+ and CD8+ T cells, we also evaluated B cell, NKT cell and NK cells infiltration after HER2-DC1 i.t. and anti-HER2 antibodies combination treatment. The gene discussed is ERBB2; the disease is neoplasm.